“…However, the response rates and PFS seen with the SCR regimen compare favourably with other less intensive induction regimens. For example, the CR rate with SCR was higher than that seen in prospective studies using BR (40%), R‐cladribine (52%), R‐CHOP (34–42%), and VR‐CAP (rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib; 53%) (Kluin‐Nelemans et al , ; Robak et al , ; Chen et al , ; Le Gouill et al , ; Visco et al , ; Chang et al , ; Ruan et al , ; Tam et al , ). Furthermore, although MRD testing was only available for 14 responding patients, all were MRD‐negative after induction.…”